Medicines Co. Stock
-
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
Cons
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0.790% | -2.788% | 4.952% | -6.894% | -1.572% | -16.404% | -9.016% |
| Opko Health Inc. | -0.710% | 1.471% | 5.376% | -23.741% | -19.568% | -3.473% | -69.899% |
| Amicus Therapeutics Inc. | 0.600% | -0.595% | 4.375% | -11.170% | -8.743% | -27.214% | -57.398% |
Comments
News
Meet the Biotech Stock That Just Jumped 251% Higher
Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue


